Gsa Capital Partners LLP Kiniksa Pharmaceuticals, Ltd. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$13.62 - $20.2 $387,734 - $575,053	28,468 Added 81.93%	63,216 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$10.44 - $16.48 $48,159 - $76,022	4,613 Added 15.31%	34,748 $489,000
Q1 2023 May 12, 2023	BUY	$10.7 - $15.79 $322,444 - $475,831	30,135 New	30,135 $324,000
Q1 2022 May 11, 2022	SELL	$9.3 - $12.37 $150,260 - $199,862	-16,157 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.39 - $15.15 $167,871 - $244,778	16,157 New	16,157 $190,000
Q4 2020 Feb 03, 2021	SELL	$14.8 - $21.15 $307,455 - $439,370	-20,774 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$15.21 - $25.53 $315,972 - $530,360	20,774 New	20,774 $318,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $690M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.